Equities research analysts predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will post earnings per share of ($0.13) for the current quarter, Zacks reports. Two analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings, with estimates ranging from ($0.18) to ($0.10). Arrowhead Pharmaceuticals reported earnings per share of ($0.31) in the same quarter last year, which suggests a positive year over year growth rate of 58.1%. The business is scheduled to announce its next quarterly earnings results on Wednesday, December 13th.

According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.50) to ($0.41). For the next year, analysts anticipate that the firm will report earnings of ($0.81) per share, with EPS estimates ranging from ($0.88) to ($0.69). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Arrowhead Pharmaceuticals.

ARWR has been the subject of several research reports. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target for the company in a research report on Monday, November 27th. William Blair raised shares of Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, September 18th. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 price target (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. Finally, BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. Arrowhead Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $3.17.

Arrowhead Pharmaceuticals (NASDAQ ARWR) traded down $0.08 during midday trading on Monday, reaching $3.49. 1,011,417 shares of the company traded hands, compared to its average volume of 771,375. Arrowhead Pharmaceuticals has a twelve month low of $1.20 and a twelve month high of $4.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.84 and a quick ratio of 3.84.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its holdings in Arrowhead Pharmaceuticals by 3.7% during the 1st quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock worth $581,000 after acquiring an additional 11,099 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Arrowhead Pharmaceuticals by 10.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after acquiring an additional 16,103 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Arrowhead Pharmaceuticals by 3.4% during the 1st quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after acquiring an additional 21,654 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Arrowhead Pharmaceuticals by 252.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 31,765 shares during the last quarter. Finally, Virtu KCG Holdings LLC boosted its holdings in Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 53,215 shares during the last quarter. 20.20% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/12/02/brokerages-expect-arrowhead-pharmaceuticals-inc-arwr-will-post-earnings-of-0-13-per-share.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.